BR112022008639A2 - Tratamento de distúrbios do fígado - Google Patents

Tratamento de distúrbios do fígado

Info

Publication number
BR112022008639A2
BR112022008639A2 BR112022008639A BR112022008639A BR112022008639A2 BR 112022008639 A2 BR112022008639 A2 BR 112022008639A2 BR 112022008639 A BR112022008639 A BR 112022008639A BR 112022008639 A BR112022008639 A BR 112022008639A BR 112022008639 A2 BR112022008639 A2 BR 112022008639A2
Authority
BR
Brazil
Prior art keywords
treatment
liver disorders
disorders
manifestations
symptoms
Prior art date
Application number
BR112022008639A
Other languages
English (en)
Portuguese (pt)
Inventor
Fenaux Martijn
Wang Yujin
Zhong Weidong
KLUCHER Kevin
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of BR112022008639A2 publication Critical patent/BR112022008639A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022008639A 2019-11-08 2020-11-06 Tratamento de distúrbios do fígado BR112022008639A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US202063004403P 2020-04-02 2020-04-02
PCT/US2020/059522 WO2021092474A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Publications (1)

Publication Number Publication Date
BR112022008639A2 true BR112022008639A2 (pt) 2022-07-19

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008639A BR112022008639A2 (pt) 2019-11-08 2020-11-06 Tratamento de distúrbios do fígado

Country Status (11)

Country Link
EP (1) EP4054567A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023501386A (cg-RX-API-DMAC7.html)
KR (1) KR20220098168A (cg-RX-API-DMAC7.html)
CN (1) CN114667142A (cg-RX-API-DMAC7.html)
AU (1) AU2020380968A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022008639A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160445A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001167A1 (cg-RX-API-DMAC7.html)
IL (1) IL292459A (cg-RX-API-DMAC7.html)
MX (1) MX2022005407A (cg-RX-API-DMAC7.html)
WO (1) WO2021092474A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259279A1 (en) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
TW202539702A (zh) * 2024-03-08 2025-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向INHBE的RNAi劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
MX2018011813A (es) * 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
EP3844156A4 (en) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISEASES

Also Published As

Publication number Publication date
CN114667142A (zh) 2022-06-24
MX2022005407A (es) 2022-05-24
CL2022001167A1 (es) 2023-02-10
WO2021092474A1 (en) 2021-05-14
IL292459A (en) 2022-06-01
CA3160445A1 (en) 2021-05-14
EP4054567A4 (en) 2024-01-10
KR20220098168A (ko) 2022-07-11
EP4054567A1 (en) 2022-09-14
AU2020380968A1 (en) 2022-05-12
JP2023501386A (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
ZA202502750B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
MX2021002305A (es) Tratamiento de trastornos del higado.
BR112018076114A2 (pt) composições tópicas de apremilast
BR112013031032A2 (pt) inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
BR112022023048A2 (pt) Tratamento de combinação de distúrbios hepáticos
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
EP3684373A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND RELIEF OF RESPIRATORY DISEASES AND MUCCOUNTAIN
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
EA201690284A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
BR112014019399A2 (pt) métodos de tratamento da fibrose
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
PH12021550671A1 (en) Prodrugs of cgrp antagonists

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]